The diagnosis and treatment of lung cancer have evolved into the era of precision medicine. Liquid biopsy, a minimally invasive approach, has emerged as a promising practice in genetic profiling and monitoring of lung cancer. Translating liquid biopsy from bench to bedside has encountered various challenges, including technique selection, protocol standardisation, data analysis and cost management. Regarding these challenges, the 2016 Chinese Lung Cancer Summit expert panel organised a trilateral forum involving oncologists, clinicians, clinical researchers, and industrial expertise on the 13th Chinese Lung Cancer Summit to formally discuss these controversies. Six consensuses were reached to guide the use of liquid biopsy and perform precision medicine in both clinic and research.
基金:
National Key Research and Development Program of China [2016YFC1303800]; Guangdong Provincial KeyLaboratory of Lung Cancer Translational Medicine [2012A061400006]; Special Fund for Researchin the Public Interest from National Health and Family Planning Commission of PRC [201402031]
第一作者单位:[1]Guangdong Gen Hosp, Guangdong Lung Canc Inst, 106 Zhongshan Er Rd, Guangzhou 510080, Guangdong, Peoples R China[2]Guangdong Acad Med Sci, 106 Zhongshan Er Rd, Guangzhou 510080, Guangdong, Peoples R China
通讯作者:
通讯机构:[1]Guangdong Gen Hosp, Guangdong Lung Canc Inst, 106 Zhongshan Er Rd, Guangzhou 510080, Guangdong, Peoples R China[2]Guangdong Acad Med Sci, 106 Zhongshan Er Rd, Guangzhou 510080, Guangdong, Peoples R China
推荐引用方式(GB/T 7714):
Wu Yi-Long,Wang Chang-Li,Sun Yan,et al.A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel[J].ESMO OPEN.2017,2:doi:10.1136/esmoopen-2017-000174.
APA:
Wu, Yi-Long,Wang, Chang-Li,Sun, Yan,Liao, Mei-Lin,Guan, Zhong-Zhen...&Zhong, Wen-Zhao.(2017).A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel.ESMO OPEN,2,
MLA:
Wu, Yi-Long,et al."A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel".ESMO OPEN 2.(2017)